123 results about "Therapeutic group" patented technology

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

The invention discloses a mouse model for treating in-situ pulmonary nodules by using bacterial lysates as well as a construction method and application of the mouse model. The method comprises the following steps: constructing an in-situ pulmonary nodule KT mouse model, instilling adenovirus, randomly dividing the model into an in-situ pulmonary nodule control group and a treatment group, performing bacterial lysate administration on mice in the treatment group at the maximum treatment dosage of 35mg / kg / d, and administering the same dosage of PBS solution to the control group. According to the invention, the possibility of killing cancer cells and preventing precancerous lesion progression by promoting autoimmunity of mice through oral immunostimulation drugs is provided for the first time, namely, the curative effect and mechanism of new drugs are researched through a mouse model, so that the clinical indications of the drugs are widened, and the blank field of clinical pulmonary nodule drug treatment is supplemented.

The invention relates to the technical field of intelligent wearing monitoring, in particular to a multifunctional head-mounted device for improving anxiety and depression symptoms in the perioperative period, which comprises a main body base, an electric treatment assembly and a power supply assembly are arranged on the main body base, extending ear hooks are arranged at two ends of the main body base, binding straps are arranged on the extending ear hooks, and a nose pad block is arranged at the bottom of the main body base. The electric treatment assembly is in signal connection with an evaluation and control system, heart rate monitoring assemblies are arranged on the extension ear hooks, and an eye movement monitoring assembly is arranged at the bottom of the main body base; a displacement monitoring assembly is arranged on the main body base, and a respiration monitoring assembly is arranged on the nose pad block. According to the invention, physiological parameter monitoring, anxiety and depression assessment and percutaneous nerve stimulation treatment functions are integrated, and multi-node fixed design and real-time dynamic data processing are combined, so that redundant steps depending on preposed medical assessment in the traditional technology are omitted, doctors can remotely and accurately adjust personalized schemes based on dynamic data, and the accuracy of diagnosis and treatment is improved. The anxiety depression intervention efficiency and reliability in the perioperative period are improved.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are histotripsy and / or ultrasound transducer arrays, and associated systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The transducer arrays provided herein can include a machined array shell having a plurality of wells formed therein. An acoustic stack including a plurality of matching and transducer elements can be disposed in the wells and be configured to transmit ultrasound energy through the plurality of matching layers and through the array shell towards a common focal point

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are histotripsy and / or ultrasound transducer arrays, and associated systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The transducer arrays provided herein can be individually tuned such that transducer arrays with different sizes, focal lengths, or transducer element sizes may work at a desired operating frequency with the same signal generator.

Provided is a process including: accessing clinical trial data of an ongoing clinical trial that is not yet complete, the clinical trial having a plurality of treatment groups and a plurality of patients in the treatment groups; detecting, with an anomaly detection model, an anomaly in the clinical trial data for a first patient, the anomaly corresponding to a first patient among the plurality of patients; in response to detecting the anomaly classifying the first patient as anomalous in the trial; generating, with the computer system, by an artificial intelligence model, a candidate explanation for the detected anomaly by designating data in a record for the first patient as potentially correlated with the anomaly; and causing the anomaly and the candidate explanation to be presented to a data safety monitoring board (“DSMB”) of the clinical trial.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

Apparatuses, systems, and methods for treating a tissue site. A system for treating a tissue site with negative pressure includes a dressing and a dressing interface. The dressing includes a cover configured to be disposed over the tissue site, a tissue interface configured to be positioned adjacent to the cover, and a wound contact layer configured to be positioned adjacent to the tissue interface. The dressing interface is configured to be coupled to the cover to fluidly couple the tissue interface and the wound contact layer to a therapy unit. The dressing interface is also configured to transmit electromagnetic radiation through the cover.

The invention provides cardiovascular intervention postoperative treatment equipment which structurally comprises a lying plate, a moving seat, a telescopic part, a positioning block and a treatment assembly, the lying plate is embedded in the upper middle area of the moving seat, the telescopic part is fixed to the lower middle area in front of the moving seat and is in interval fit with the lying plate, and the positioning block is fixedly connected with the other end of the telescopic part; the treatment assembly is arranged at the upper end of the positioning block and is horizontally communicated with the lying plate; after the lying plate is further improved, the inner side of the plate body is completely covered by the sponge cushion, so that the back bone of a patient can be prevented from being in direct contact with the plate body, and the pain caused by the influence of the hardness of the plate body on the back bone is prevented; then, the infrared positioner on the plate body can be matched with the top part of the treatment assembly in a light induction mode through the infrared generating body of the infrared positioner, so that the cardiovascular treatment area of the patient can be determined through infrared induction instead of medical staff, and therefore the position determination accuracy and efficiency can be improved.

The present disclosure provides therapeutic combinations, which provide a synergistic effect in treating a cancer. The present disclosure provides methods of treatment including administration of the combinations, and uses of the combinations, e.g., for treatment of cancer.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The histotripsy therapy system can include a robotic positioning system configured to move and translate an ultrasound transducer array through a treatment volume.

The application discloses application of pentagalloyl glucose (PGG) in preparation of an anti-doxorubicin cardiotoxicity medicine. The process is as follows: a myocardial cell H9C2 injury model is induced and established by doxorubicin (DOX), and a minimum concentration of the myocardial cell injury induced by DOX is determined. After 20 muM of PGG is added to a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and the ejection fraction (EF%) of mice in the doxorubicin+pentagalloyl glucose group are significantly increased, the myocardial fiber structure is improved, cytoplasm vacuolization is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. It is proved by the above experiments that the pentagalloyl glucose can significantly reduce DOX-induced myocardial toxicity.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The invention relates to the technical field of clinical application, and discloses preparation and clinical application of Deyu large plaster, the raw materials of the Deyu large plaster comprise fritillaria, deer sinew, honeysuckle and other medicinal materials, yellow lead and sesame oil are supplemented, and the Deyu large plaster is prepared through the steps of preparing and soaking, decocting, adding the yellow lead, removing fire toxin, removing mud, packaging and the like. In the medicinal materials, the fritillaria clears heat and moistens lung, the deer sinew nourishes liver and kidney and strengthens muscles and bones, and the honeysuckle has antibacterial and anti-inflammatory effects, and the medicines are compatible to achieve the effects of strengthening tendons and bones, nourishing blood and dredging collaterals. Clinically, 520 patients with neck, shoulder, waist and leg pain are divided into a treatment group (320 patients use Deyu large plaster) and a control group (200 patients use collateral dredging and pain relieving plaster), after 10 days of treatment course, 102 patients are cured in the treatment group, 131 patients are effective, the total effective rate is 94%, the total effective rate of the control group is 81%, and the difference between the two groups is remarkable (plt: 0.05). The plaster is small in adverse reaction, suitable for long-term use and remarkable in curative effect in treatment of neck-shoulder and lumbocrural pain.

An ergonomic and unobtrusive cardiac monitoring and treatment device with separable monitoring and treatment components includes a first wearable portion, a second wearable portion separable from the first wearable portion, and a device controller. The device controller includes at least one processor and an output device. The first wearable portion includes an elongated strap configured to encircle a thoracic region, ECG sensing electrodes permanently formed into the strap, a driven ground electrode, and conductive wires configured to couple the sensing electrodes with the controller. The second wearable portion includes a wearable substrate configured to be worn over at least one shoulder, one or more treatment electrodes configured to provide a therapeutic shock to the patient, and at least one additional conductive wire configured to releasably connect the treatment electrode(s) to the controller. The output device is configured to provide a notification instructing the patient to wear the second wearable portion.

The present invention addresses the problem of providing: a novel treatment strategy using a molecular targeted drug in cancer patients having a driver mutation; a novel method capable of identifying a treatment target patient group suitable for the novel treatment strategy, and capable of predicting, monitoring, or diagnosing a response to the novel treatment strategy; and a kit for use in the method. The present invention provides, as a means for solving the problem, a pharmaceutical composition which contains, as an active ingredient, a FAK inhibitor and a RAF / MEK dual inhibitor for use in the treatment of, for example, patients suffering from cancer, and which is for administration to patients who have been confirmed that an epithelial biomarker expression level in a tumor sample isolated from a patient is higher than the mesenchymal biomarker expression level.

The invention discloses an adaptive random-based clinical test allocation method, system and device, and a storage medium, and the method comprises the steps: randomly allocating subjects to each treatment group according to a preset proportion, and obtaining the current curative effect data of each treatment group; determining the posterior probability of each treatment group based on the current curative effect data of each treatment group, and adjusting the random distribution probability according to the posterior probability; determining the condition test efficiency of each treatment group, and executing a preset resource optimization strategy on each treatment group according to the condition test efficiency to obtain a test result; and determining the current posterior probability of each treatment group according to the test result, and determining the optimal treatment group based on the current posterior probability. The random distribution probability of each treatment group is dynamically adjusted in the test process, the preset resource optimization strategy is executed on each treatment group according to the condition test efficiency, and the target treatment group is determined based on the test result, so that the subject distribution in the test is optimized, and the reliability and the accuracy of the test result are improved.

A device may establish communication between the plurality of intelligent injection devices and an artificial intelligence-powered clinical research platform configured to manage a clinical trial or research program. A device may analyze, via the artificial intelligence platform, clinical trial protocol requirements including study design parameters, randomization schemes, blinding protocols, and adverse event monitoring requirements to generate coordinated medication administration strategies across the plurality of intelligent injection devices. A device may apply research protocol constraints to restrict medication selection, dosage calculations, administration timing, and patient assignment across the plurality of intelligent injection devices. A device may generate real-time coordination instructions through the artificial intelligence platform including synchronized administration timing across multiple sites, dosage verification protocols for different treatment arms, and compliance monitoring procedures tailored to specific research protocol requirements.

The application of FBH1 protein in judging the efficacy of postoperative somatostatin analogue adjuvant therapy for pancreatic neuroendocrine tumors relates to the fields of proteomics and clinical detection technology. The present invention finds that the disease-free survival and total survival time of the postoperative SSA adjuvant therapy group of PNETs patients with high FBH1 expression are significantly better than those of the non-adjuvant therapy group. By detecting the relative content of FBH1 protein in the tumor tissue of PNETs patients, it is effective to evaluate whether the patients use SSA drug adjuvant therapy after surgery, which is of great significance for the guidance of postoperative medication for patients.

Conventional hospital management support systems are limited to a relative evaluation of patient attributes and medical departments, and do not accurately grasp the profitability and costs of each disease or treatment group. This makes it difficult to perform specific data analysis that directly leads to optimal allocation of medical resources, improved treatment efficiency, and management improvements. [Solution] This invention provides a "patient grouping management module" that groups patients based on specific treatments or diseases, and calculates and visualizes the profitability, costs, and profit margins of each group. Furthermore, by calculating management indicators for each patient group based on medical fees, drug price margins, and material margins, and visualizing and analyzing the results in real time, it builds a management support system that allows doctors and managers to specifically plan resource allocation and treatment strategies.

A therapy assembly can have an inner layer having an inner surface and an outer surface and defining a plurality of openings extending therethrough. The therapy assembly can also include a plurality of plates, each plate at least partially received within a respective opening of the plurality of openings of the inner layer. The therapy assembly can also include therapy circuitry including a cable having a plurality of electrical leads and a plurality of lead ends, each electrical lead electrically connected to a respective lead end of the plurality of lead ends. A cover layer can be attached to the outer surface of the inner layer and cover the plurality of lead ends of the cable. The plurality of lead ends can be in contact with a respective plate of the plurality of plates to define a plurality of electrodes.

The treatment head comprises a housing, a treatment assembly and a detection assembly, the housing is provided with a treatment surface used for contacting a part to be treated, an accommodating space is formed in the housing, and the treatment surface is provided with an opening communicated with the accommodating space; the treatment assembly is arranged in the containing space, partially exposed out of the opening and used for making contact with a to-be-treated part, and at least part of the outer wall of the treatment assembly and the inner wall of the shell are arranged in a spaced mode so as to define a mounting space communicated with the opening; the detection assembly is arranged in the installation space and faces the opening so as to detect the fitting condition of the treatment end and the to-be-treated part through the opening. According to the technical scheme, contact detection can be achieved in a non-pressure-sensitive detection mode, and the use experience of a user is improved.

To provide methods and compositions for preventing or treating (e.g., slowing the progression of, arresting and / or reversing) tissue calcification in a subject in need of the prevention or treatment of the tissue calcification.SOLUTION: The invention provides methods of using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7) for preventing or treating tissue calcification in a subject with diabetes, chronic kidney disease, end-stage renal failure, or a subject undergoing hemodialysis and / or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7), for preventing or treating the one or more symptoms of COPD.SELECTED DRAWING: None

The invention discloses an application of a Gal-9 + Th cell and / or Gal-9 + Treg as an AIH detection target spot. Researches find that compared with a healthy control group, the peripheral blood Gal-9 + Treg cell proportion and Gal-9 + Th cell proportion of an AIH patient baseline group are remarkably increased, and after ALT of a patient in a treatment group returns to normal, the Gal-9 + Treg cell proportion and the Gal-9 + Th cell proportion are both decreased compared with those before treatment, and it is indicated that the Gal-9 + Treg cell proportion and the Gal-9 + Th cell proportion are effective indexes for monitoring disease improvement. However, the AIH is a chronic disease process, even if the ALT level returns to normal, Gal-9 + Treg cells and Gal-9 + Th cells still do not return to the level of a healthy control group, the Gal-9 + Th cells are taken as detection targets, the progress of the AIH disease course can be monitored more accurately, and disease repetition and biochemical rebounding caused by premature drug withdrawal are prevented.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features such as planning and implementation of an adaptive distribution of cooling periods across a treatment volume of tissue given various treatment depths and voltages. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures for tissue cooling. Other embodiments are described herein.

Systems, methods, and apparatuses for treating a tissue site are described. In some embodiments, the system may include a dressing, a negative-pressure source, and a communication device. The communication device may be coupled to the negative-pressure source and configured to transmit operational data of the negative pressure source to a remote location for monitoring usage of the system.

This invention discloses a seated rehabilitation training device, comprising a base, a seated platform mounted on the base, and a column mounted at each of the four corners of the base. Two sets of treatment components are slidably connected between adjacent columns. A top frame is mounted on the top of each column, and a traction component is mounted on the top frame. The treatment components include a mounting box, a push rod, a guide slider, and a push pillow. The traction component includes two parallel first pulleys, multiple spaced second pulleys, a traction rope, and a traction frame. An airbag device is connected to each column. This invention integrates three core rehabilitation functions—spinal traction, multi-directional mechanical compression, and airbag pressure therapy—into a single device. Patients can receive combined traction and multi-directional compression treatment sequentially or simultaneously on the same device and in the same posture, achieving synergistic therapeutic force and effectively overcoming the drawbacks of traditional therapies that require switching between different devices and fragmented treatment processes.

The application provides a kind of treatment auxiliary mechanical arm equipment, wherein first treatment component, second treatment component can be moved along column to adjust position;First treatment component includes first support arm and first treatment probe mounting portion connected at the end of first support arm, first treatment probe mounting portion includes first mounting seat and first mounting clamp elastically movably connected with first mounting seat, first mounting clamp is used to install first treatment probe, first mounting clamp makes first treatment probe closely adhere to treatment site by elastic force, and the structure of second treatment component is similar.In the application, first treatment component and second treatment component can be adjusted with multiple degrees of freedom similar to human arm, and can be used in combination, so that the treatment probe accurately corresponds to the lesion site for treatment, and can maintain the close state to ensure the treatment effect, improve the reliability and convenience of treatment, especially urological treatment, and reduce the workload of medical staff.